NCT06274554View on ClinicalTrials.gov

Testing the Role of Anti-fungal Therapy in Improving the Response to Therapies for Crohn's Disease

PHASE3RecruitingINTERVENTIONAL
Enrollment

120

Participants

Timeline

Start Date

October 4, 2024

Primary Completion Date

December 31, 2028

Study Completion Date

December 31, 2029

Conditions
Crohn's DiseaseInflammatory Bowel Diseases
Interventions
DRUG

Fluconazole

Oral fluconazole capsules.

DRUG

Placebo

Oral placebo capsules will be used as a comparator.

BIOLOGICAL

IL-23 Therapy

Risankizumab (IL-23), Guselkumab (IL-23), or Ustekinumab (IL-12/23) as standard of care treatment.

Trial Locations (1)

10065

RECRUITING

Weill Cornell Medicine, New York

All Listed Sponsors
collaborator

The Leona M. and Harry B. Helmsley Charitable Trust

OTHER

lead

Weill Medical College of Cornell University

OTHER